Page 2 - Pharma Sales

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

After showing signs of recovery in June, domestic pharma sales dip in July

Data shows that the Covid-19 crisis impacted the growth rate of the domestic market

Green shoots seen in June pharma sales as domestic market grows 2.4%

The turn around follows deep decline in sales in the preceding months; July sales likely to be flat

Hyderabad's Raghav Life Sciences develops Favipiravir for Covid-19 patients

Firm says it has been in talks with at least eight buyers, including a few overseas companies, to supply the anti-retroviral drug

Price drives Indian pharmaceutical market growth to five-year high in FY20

Ipca's Zerodol brand and its multiple variants used in treating pain and inflammation are an example of how this trend is playing out

Stricter regulations, pricing control slow down pharma sector growth

The fifth part of the series looks at what's ailing the pharma sector

Pharma sales growth hit 19-month low in May as product launches slowed down

For the first time, all chronic therapy drugs grew only in single digits during May

Pharma sales growth on double-digit track, back to pre-GST disruption level

Among top Indian players, Delhi based-Mankind Pharma showed the highest growth at 17.9%

Domestic pharmaceutical sales growth at eight year low, slips to 5.5%

GST, price caps impact sales but drug makers optimistic of growth revival in 2018

Pharma sales remain subdued in first week

Drug makers have offered 6.5-8.5% incentives to stockists